公开(公告)号：WO9922810A9

公开(公告)日：1999-08-19

申请号：PCT/US9823649

申请日：1998-11-04

Applicant: HISAMITSU PHARMACEUTICAL CO ,  MORI KENJI ,  NOZAWA IWAO ,  SATO SHUJI

Inventor： MORI KENJI ,  NOZAWA IWAO ,  SATO SHUJI

IPC: A61N1/30 ,  A61N1/32

CPC classification number: A61N1/0424 ,  A61N1/042 ,  A61N1/044 ,  A61N1/0444 ,  A61N1/327

Abstract: Electroporation electrodes (12, 22) are laminated to a permeable membrane (11, 21) to form an electrode membrane. Such an electrode membrane is useful for a continuous controlled delivery of a therapeutic agent through the skin or mucosa when placed in direct contact with the skin or mucosa, and by application of electric field pulses at specified intervals. An electrode membrane can be assembled such that it incorporates an iontophoretic electrode in the same device. The device can be jointly utilized for electroporation, for iontophoretic drug delivery through the skin, and mucosal membrane.

Abstract translation: 将电穿孔电极（12,22）层叠到可渗透膜（11,21）上以形成电极膜。 这样的电极膜可用于当与皮肤或粘膜直接接触时通过皮肤或粘膜连续控制递送治疗剂，并且以规定的间隔施加电场脉冲。 可以组装电极膜，使得其在同一装置中并入离子电渗电极。 该装置可以共同用于电穿孔，用于通过皮肤的离子电渗药物递送和粘膜。

公开(公告)号：WO9923208A3

公开(公告)日：1999-07-22

申请号：PCT/IB9801837

申请日：1998-10-29

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： VEERAPANENI DANGE ,  HAMANAKA SHAII ,  NOZAWA IWAO

IPC: A01K67/027 ,  A61K31/7105 ,  A61K38/00 ,  A61P19/02 ,  A61P29/00 ,  C12N5/10 ,  C12N9/12 ,  C12N15/09 ,  C12N15/113 ,  C12N15/11 ,  A61K31/70 ,  C07H21/00 ,  C12N9/00

CPC classification number: C12N15/1136 ,  A01K2217/05 ,  A61K38/00 ,  C12N2310/121 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/53

Abstract: Enzymatic RNA molecules which cleave mRNA encoding IL-15, are provided. The constructs of the invention include regulatory regions for expression in cells, cell lines, or transgenic non-human animals. The ribozymes of the invention are directed against IL-15 mRNA and are useful in treating rheumatoid arthritis.

Abstract translation: 提供了切割编码IL-15的mRNA的酶RNA分子。 本发明的构建体包括用于在细胞，细胞系或转基因非人动物中表达的调节区。 本发明的核酶针对IL-15mRNA，并且可用于治疗类风湿性关节炎。

公开(公告)号：JPH10127293A

公开(公告)日：1998-05-19

申请号：JP12649397

申请日：1997-04-30

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： DANJE BERAPANANE ,  NOZAWA IWAO

IPC: C12N15/09 ,  A61K31/70 ,  A61K48/00 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113 ,  C12P19/34

Abstract: PROBLEM TO BE SOLVED: To obtain a conjugant of an oligonucleotide with a carbohydrate having resistance to a nuclease decomposition and used for an inhibitor against gene expression by bonding the oligonucleotide with the carbohydrate through a synthesized compound without existing in natural, not being a protein and having a high molecular weight. SOLUTION: This conjugation of an oligonucleotide with a carbohydrate is a new compound having an oligonucleotide, an electrically neutral, synthesized and cross-linked material formed between the oligonucleotide and a carbohydrate, without existing in natural, not being a protein, having

公开(公告)号：DE69332276T2

公开(公告)日：2003-01-09

申请号：DE69332276

申请日：1993-04-09

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： SATO SYUJI ,  NOZAWA IWAO ,  AKIYAMA KATSUHIKO

IPC: A61K9/127 ,  A61K47/48 ,  A61K47/24 ,  A61K47/28

Abstract: A liposome composition effective in administering a physiologically active substance to Peyer's glands. It has a high ability to migrate toward Peyer's glands and contains phosphatidylcholine, cholesterol and phosphatidylinositol as lipid components.

公开(公告)号：AU720110B2

公开(公告)日：2000-05-25

申请号：AU4331497

申请日：1997-08-29

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： VEERAPANANE DANGE ,  HAMANAKA SHOJI ,  NOZAWA IWAO

IPC: C12N15/09 ,  A61K31/7125 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61P11/06 ,  A61P19/02 ,  C12N15/113 ,  C07H21/04

Abstract: Oligomers for inhibiting expression of interleukin genes are described. It is believed that each oligomer, when introduced into a cell, is capable of forming a transcription-inhibiting complex composed of the oligomer and an interleukin gene. The oligomer preferably binds in the antiparallel orientation to the polypurine strand of a polypurine-polypyrimidine region of the interleukin gene.

公开(公告)号：CA2332699A1

公开(公告)日：2000-01-13

申请号：CA2332699

申请日：1999-07-07

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： HAMANAKA SHOJI ,  NOZAWA IWAO ,  HIROYUKI KUBO ,  VEERAPANANE DANGE

IPC: C12N15/09 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7125 ,  A61K35/76 ,  A61K38/00 ,  A61K47/48 ,  A61K48/00 ,  A61P1/04 ,  A61P1/18 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P35/00 ,  C07H21/04 ,  C12N15/113 ,  C12Q1/68 ,  C12N15/00 ,  C12N15/85 ,  C12N15/86

Abstract: The invention features antisense oligonucleotide molecules that specifically bind polynucleotides encoding IL-15. The present invention provides antisens e oligonucleotides capable of inhibiting IL-15 expression, and methods of use thereof to reduce activity of IL-15 in tissues in order to treat diseases su ch as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, chronic liver disease, ulcerative colitis and cell proliferative disorders.

公开(公告)号：AU1312099A

公开(公告)日：1999-05-24

申请号：AU1312099

申请日：1998-11-04

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： MORI KENJI ,  NOZAWA IWAO ,  SATO SHUJI

IPC: A61N1/30 ,  A61N1/32

公开(公告)号：AT223204T

公开(公告)日：2002-09-15

申请号：AT93908075

申请日：1993-04-09

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： SATO SYUJI ,  NOZAWA IWAO ,  AKIYAMA KATSUHIKO

IPC: A61K9/127 ,  A61K47/48 ,  A61K47/24 ,  A61K47/28

Abstract: A liposome composition effective in administering a physiologically active substance to Peyer's glands. It has a high ability to migrate toward Peyer's glands and contains phosphatidylcholine, cholesterol and phosphatidylinositol as lipid components.

公开(公告)号：AU5093899A

公开(公告)日：2000-01-24

申请号：AU5093899

申请日：1999-07-07

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： VEERAPANANE DANGE ,  HAMANAKA SHOJI ,  HIROYUKI KUBO ,  NOZAWA IWAO

IPC: C12N15/09 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7125 ,  A61K35/76 ,  A61K38/00 ,  A61K47/48 ,  A61K48/00 ,  A61P1/04 ,  A61P1/18 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P35/00 ,  C07H21/04 ,  C12N15/113 ,  C12Q1/68 ,  C12N15/00 ,  C12N15/85 ,  C12N15/86

Abstract: The invention features antisense oligonucleotide molecules that specifically bind polynucleotides encoding IL-15. The present invention provides antisense oligonucleotides capable of inhibiting IL-15 expression, and methods of use thereof to reduce activity of IL-15 in tissues in order to treat diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, chronic liver disease, ulcerative colitis and cell proliferative disorders.

公开(公告)号：CA2117769A1

公开(公告)日：1993-10-11

申请号：CA2117769

申请日：1993-04-09

Applicant: HISAMITSU PHARMACEUTICAL CO

Inventor： SATO SHUJI ,  NOZAWA IWAO ,  AKIYAMA KATSUHIKO

IPC: A61K9/127 ,  A61K47/48 ,  A61K47/24 ,  A61K47/28

Abstract: A liposome composition which is effective in administering a physiologically active substance to Peyer's patches and is characterized by containing phosphatidylcholine, cholesterol and phosphatidylinositol as lipid components and having a high ability to migrate into Peyer's patches.